We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
J&J Ends Imaavy Development in Rheumatoid Arthritis Post Study Failure
Read MoreHide Full Article
Key Takeaways
J&J is discontinuing Imaavy's RA development after phase IIa results showed no added benefit.
The DAISY study tested Imaavy plus anti-TNF aplha in refractory RA but did not improve outcomes.
J&J still projects Imaavy as a $5B+ sales driver, with trials ongoing in multiple immune disorders.
Johnson & Johnson (JNJ - Free Report) announced that it is discontinuing the development of an investigational combination therapy involving Imaavy (nipocalimab) in the rheumatoid arthritis (RA) indication.
This decision is based on findings from the phase IIa DAISY proof-of-concept study, which tested Imaavy in combination with an anti-tumor necrosis factor alpha (anti-TNFα) in RA patients with refractory disease. The study results did not show “sufficient evidence” that the combo treatment provided a significant added benefit compared with anti-TNFα therapy alone. J&J did not report any safety concerns in the study.
Imaavy is the first and only neonatal Fc receptor (FcRn) blocker approved by the FDA to treat generalized myasthenia gravis (gMG) in patients aged 12 years and older who are anti-AChR and anti-MuSK antibody positive. This approval was secured by J&J in April.
JNJ Stock Performance
Year to date, the stock has gained 21% against the industry’s nearly 1% decline.
Image Source: Zacks Investment Research
J&J Reiterates $5B+ Sales Potential With Imaavy
Despite the setback in RA indication, the pharma giant assured investors that it still expects Imaavy to be a potential key driver of top-line growth. J&J believes the drug is one of the ten new Innovative Medicine products that have the potential to deliver peak sales of $5 billion. This list of potential blockbusters also includes new cancer drugs like Talvey and Tecvayli, a newly acquired drug, Caplyta and pipeline candidates like TAR-200 and icotrokinra.
J&J is evaluating the drug in an ongoing clinical program across several immunology and neuroscience indications. This includes late-stage studies for chronic inflammatory demyelinating polyneuropathy (CIDP), hemolytic disease of the fetus and newborn (HDFN), warm autoimmune hemolytic anemia (wAIHA) and Sjogren's disease.
Imaavy is also being evaluated in separate mid-stage studies for idiopathic inflammatory myopathy and systemic lupus erythematosus indications.
In the past 60 days, estimates for ANI Pharmaceuticals’ 2025 earnings per share (EPS) have risen from $6.51 to $7.25. EPS estimates for 2026 have increased from $7.05 to $7.74 during the same period. Year to date, shares of ANIP have surged over 67%.
ANIP’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 22.66%.
Estimates for CorMedix’s 2025 EPS have increased from 93 cents to $1.22 over the past 60 days, while the same for 2026 has increased from $1.64 to $2.12. CRMD shares have soared 77% year to date.
CorMedix’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 34.85%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
J&J Ends Imaavy Development in Rheumatoid Arthritis Post Study Failure
Key Takeaways
Johnson & Johnson (JNJ - Free Report) announced that it is discontinuing the development of an investigational combination therapy involving Imaavy (nipocalimab) in the rheumatoid arthritis (RA) indication.
This decision is based on findings from the phase IIa DAISY proof-of-concept study, which tested Imaavy in combination with an anti-tumor necrosis factor alpha (anti-TNFα) in RA patients with refractory disease. The study results did not show “sufficient evidence” that the combo treatment provided a significant added benefit compared with anti-TNFα therapy alone. J&J did not report any safety concerns in the study.
Imaavy is the first and only neonatal Fc receptor (FcRn) blocker approved by the FDA to treat generalized myasthenia gravis (gMG) in patients aged 12 years and older who are anti-AChR and anti-MuSK antibody positive. This approval was secured by J&J in April.
JNJ Stock Performance
Year to date, the stock has gained 21% against the industry’s nearly 1% decline.
Image Source: Zacks Investment Research
J&J Reiterates $5B+ Sales Potential With Imaavy
Despite the setback in RA indication, the pharma giant assured investors that it still expects Imaavy to be a potential key driver of top-line growth. J&J believes the drug is one of the ten new Innovative Medicine products that have the potential to deliver peak sales of $5 billion. This list of potential blockbusters also includes new cancer drugs like Talvey and Tecvayli, a newly acquired drug, Caplyta and pipeline candidates like TAR-200 and icotrokinra.
J&J is evaluating the drug in an ongoing clinical program across several immunology and neuroscience indications. This includes late-stage studies for chronic inflammatory demyelinating polyneuropathy (CIDP), hemolytic disease of the fetus and newborn (HDFN), warm autoimmune hemolytic anemia (wAIHA) and Sjogren's disease.
Imaavy is also being evaluated in separate mid-stage studies for idiopathic inflammatory myopathy and systemic lupus erythematosus indications.
JNJ’s Zacks Rank
J&J currently carries a Zacks Rank #2 (Buy).
Johnson & Johnson Price
Johnson & Johnson price | Johnson & Johnson Quote
Other Key Picks Among Biotech Stocks
Some other better-ranked stocks from the sector are ANI Pharmaceuticals (ANIP - Free Report) and CorMedix (CRMD - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for ANI Pharmaceuticals’ 2025 earnings per share (EPS) have risen from $6.51 to $7.25. EPS estimates for 2026 have increased from $7.05 to $7.74 during the same period. Year to date, shares of ANIP have surged over 67%.
ANIP’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 22.66%.
Estimates for CorMedix’s 2025 EPS have increased from 93 cents to $1.22 over the past 60 days, while the same for 2026 has increased from $1.64 to $2.12. CRMD shares have soared 77% year to date.
CorMedix’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 34.85%.